A group of researchers started this project with the aims of understanding what are the core outcomes for patients living with Long COVID.
On its 10th anniversary, University of Oxford’s ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) demonstrates the crucial role of global preparedness and collaboration for advancing knowledge on infectious disease pandemics.
Children older than 6 and with reported allergic diseases are at greater risk of Long COVID, paediatric study finds
Researchers from ISARIC (International Severe Acute Respiratory and emerging Infection Consortium) paediatric Long Covid working group in the UK, Sechenov University and Z.A. Bashlyaeva Children’s Municipal Clinical Hospital in Russia ran the largest study to date on children hospitalised with COVID 19.
Women under 50 and people who experienced severe disease had worse long-term outcomes following hospitalisation with COVID-19.
ISARIC, supported by the UK Coronavirus Immunology Consortium (UK-CIC), has identified new biomarkers of inflammation that both indicate the severity of COVID-19 and distinguish it from severe influenza.
The Lancet Infectious Diseases published the GloPID-R and ISARIC Long COVID Forum Working Group’ letter, describing the content and discussions of the Long COVID Forum which took place on 9-10 December 2020.
Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data
“These regional differences in mortality reflect differences in access to better health care that already existed before the pandemic”, explains Fernando Bozza, study coordinator and researcher at the National Institute of Infectious Disease.
Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study
The QCOVID is a new risk prediction tool that uses readily available information about people, such as their age, ethnicity and whether they have certain comorbidities to help identify individuals at highest risk of developing severe illness.
“Genetic evidence is second only to clinical trials as a way to tell which treatments will be effective in a disease.”
The long-term health consequences of COVID-19 remain largely unclear. The aim of this study was to describe the long-term health consequences of patients with COVID-19 who have been discharged from hospital and investigate the associated risk factors, in particular disease severity.
In January 2020, ISARIC launched an international initiative for standardised COVID-19 clinical data collection. Over the past nine months, there has been extensive global participation, resulting in one of the world’s largest collections of comprehensive clinical data for COVID-19.
ISARIC, based at Oxford University, in collaboration with Dr Janet Scott, of the MRC-University of Glasgow’s Centre for Virus Research, has launched a longitudinal observational study to measure prevalence and risk factors of long-term health and psychosocial consequences of COVID-19.
The international, multi-site study is launched by ISARIC to measure prevalence and risk factors of long-term health and psychosocial consequences of COVID-19. The researchers are inviting hospitals and healthcare sites worldwide to join this new study.
Even as the COVID-19 pandemic enters into its ninth month, much remains unknown about the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and COVID-19 disease. One such area is the possible long-term consequences of SARS-CoV-2 infection and the risk factors for pathological conditions resulting from the disease.
A major UK research study into the long-term health impacts of COVID-19 on hospitalised patients, involving researchers from the University of Liverpool, has been launched. The PHOSP-COVID study has been awarded £8.4million jointly by UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR).
Various clinical trial networks are being funded by GloPID-R members to ensure a rapid clinical research response to epidemics. The Clinical Trial Networks Working Group (CTN WG) provides the opportunity for networks like ISARIC to meet regularly and learn about each other’s work.
As part of the response to the emergence of COVID-19, the World Health Organization Africa Regional Office (WHO/AFRO) is organising various infection, prevention and control (IPC) and critical care training activities targeted at low- and middle-income countries in Africa.
Professor Peter Horby summarizes ISARIC's recently launched international protocol which will enable investigators to manage all the data and samples they've collected.
The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) is adapting its existing tools, designed for emerging respiratory pathogens, for the current outbreak of global significance.
ISARIC has signed a new statement on sharing research findings and data relevant to the Ebola outbreak in the Democratic Republic of Congo. Anyone interested in signing should get in touch with Katherine Littler (K.Littler@wellcome.ac.uk) directly.
A review of the extra-pulmonary complications of influenza infection.
First Ebola survivors in Sierra Leone have donated plasma within the Ebola_CP trial led by Calum Semple (ISARIC WG2 Chair) and a team of scientists at the University of Liverpool and the College of Medicine and Allied Health Services, in Sierra Leone.